Results 181 to 190 of about 176,394 (255)

Older Patients With Memory Complaints Often Prefer Diagnostics in Primary Care or No Further Diagnostic Evaluation. [PDF]

Int J Geriatr Psychiatry
Ronner D, Richard E, van Charante EPM, van Gool WA, Schers HJ, Perry M.   +5 more
europepmc   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

UK consensus guidelines for multidisciplinary care of children and young people with achondroplasia: a modified Delphi process. [PDF]

Arch Dis Child
Candler TP, Ali K, Bewick E, Borg SA, Chinoy A, Cobourne MT, Cocca A, Freeman A, Gibbins J, Gosnell E, Harrison M, Johnson K, Latimer M, McDevitt H, Murch O, Nadar R, Offiah AC, Parks C, Skae M, Smithson SF, Tucker I, Turcu S, Webb EA, Wright M, Cheung MS.   +24 more
europepmc   +1 more source

Movement Disorders in Aicardi–Goutières Syndrome and Response to Immunomodulation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This study characterizes movement disorders and treatment responses in seven children with Aicardi–Goutières syndrome (AGS). We retrospectively evaluated motor phenotypes, neuroimaging, and interferon signatures in patients treated with baricitinib or anifrolumab. Spasticity affected all patients, while dystonia was present in 4/7.
Enrique Gonzalez Saez‐Diez, Monica Ferrer Socorro, Kathryn Yang, Nicole Battaglia, Zainab Zaman, Mariko Bennett, Adeline Vanderver, Pui Y. Lee, Lauren A. Henderson, Milena M. Andzelm, Darius Ebrahimi‐Fakhari   +10 more
wiley   +1 more source

BRCA Testing in Asian Patients with Ovarian Cancer: Standard Clinical Practice or Mutation Prediction Model? [PDF]

Cancer Epidemiol Biomarkers Prev
Ang BH, Yoon SY, Lim J, Hassan NT, Tai MC, Wong ZL, Chow JY, Lee XW, Thong MK, Ch'ng GS, Omar J, Yong CM, Aliyas I, Abdul Malik R, Subramaniam S, Sim WW, Lim CS, Lee SJ, Lim KJ, Shafiee MN, Ismail F, Ismail MP, Kumarasamy S, Low JSH, Ahmad Mustafa AM, Makanjang MJ, Tayib S, Cheah NLC, Fong CK, Ho KF, Deniel A, Ang SF, Ahmad Badruddin AR, Tho LM, Woo YL, Ho WK, Teo SH.   +36 more
europepmc   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Comprehensive Characterization of 98 Chinese Cases of Genetic Creutzfeldt‐Jakob Disease With T188K Mutation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterize the demographic, clinical, and laboratory features of the Chinese patients of genetic Creutzfeldt‐Jakob disease with T188K variant (T188K‐gCJD), the most common subtype of genetic prion diseases (gPrDs) in China. Methods In this nationwide retrospective study, data from 98 genetically confirmed T188K‐gCJD patients ...
Chun‐Jie Li, Dong‐Lin Liang, Li‐Ping Gao, Wei‐Wei Zhang, Wei Zhou, A. Ruhan, Bing Xu, Run‐Dong Cao, Kang Xiao, Cao Chen, Qi Shi, Xiao‐Ping Dong   +11 more
wiley   +1 more source

Why physicians underuse patient-reported outcomes in atopic dermatitis and chronic urticaria - Insights from the UCARE/ADCARE PROMUSE study. [PDF]

World Allergy Organ J
Cherrez-Ojeda I, Robles-Velasco K, Giménez-Arnau A, Godse K, Krasowska D, Bartosińska J, Szczepanik-Kułak P, Wawrzycki B, Kolkhir P, Allenova A, Allenov A, Tkachenko S, Mitrevska NT, Mijakoski D, Stoleski S, Kolacinska-Flont M, Kuprys-Lipinska I, Molinska J, Kasperska-Zając A, Zajac M, Zamlynski M, Mihaltan F, Ulmeanu R, Zalewska-Janowska A, Tomaszewska K, Al-Ahmad M, Al-Nesf MA, Abhs M, Ibrahim T, Agel S, Pesqué D, Rodríguez-González M, Wakida-Kuzunoki GH, Ramon GD, Ramon GN, Neisinger S, Bonnekoh H, Rukhadze M, Khoshkhui M, Aliabadi MM, Fomina D, Larenas-Linnemann D, Košnik M, Kara RO, Caballero López CG, Liu Q, Ivancevich JC, Ensina LF, Rosario N, Kvedariene V, Ben-Shoshan M, Jardim Criado RF, Bauer A, Cherrez A, Chong-Neto H, Rojo-Guierrez MI, Rudenko M, Larco Sousa JI, Lesiak A, Matos E, Muñoz N, Moreno J, Tinoco I, Faytong-Haro M, Bousquet J, Zuberbier T.   +65 more
europepmc   +1 more source

Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree, Beatrice Suero, Sarah Walsh, Romain Marignier, John W. Lindsey, Ho Jin Kim, Dewei She, Daniel Cimbora, Dustin Cavida, Friedemann Paul   +9 more
wiley   +1 more source

Improving access to surgical care for Inuit communities in Nunavik: a cost-savings analysis of a surgeon outreach program. [PDF]

Can J Surg
Mashal S, Caminsky NG, Campbell JR, Boulanger N, Watt L, Grushka JR, Fata P, Deckelbaum DL, Khwaja K, McKendy K, Jastaniah A, Wong E.   +11 more
europepmc   +1 more source